AbCellera Biologics, Inc. ABCL 深 滬
等待開盤 12-25 09:30:00 美东时间
3.72
+0.030
+0.81%
華盛通- 最 高3.73
- 今 開3.71
- 成交量 172.00万股
- 最 低 3.58
- 昨 收 3.69
- 總市值 11.09亿
- 52周最高 6.515
- 市盈率 靜 --
- 換手率 0.58%
- 52周最低 1.8906
- 委 比 79.90%
- 總股本 2.98亿
- 歷史最高 71.91
- 量 比 0.47
- 振 幅 4.07%
- 歷史最低 1.8906
- 每 手 1
- 風險率 1.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AbCellera Strikes Patent License Deal With Bruker; Bruker To Pay $36M As Future Royalty Payments On Sales Of Beacon Optofluidic Platform Globally
AbCellera (Nasdaq: ABCL) today announced that it has entered into a settlement and patent license agreement with Bruker Corporation, resolving the patent litigation between the two companies globally. As part of the
12-18 22:09
AbCellera Appoints Dr. Stephen Quake to Board
AbCellera Biologics ( ($ABCL) ) has issued an announcement. On November 10, 202...
11-13 03:17
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Prelude Therapeutics reported Q3 2025 financials with $58.2M in cash and a runway into 2027. Key pipeline updates include advancing JAK2V617F inhibitor and KAT6A degrader candidates, with IND filings expected in 2026. The company also presented preclinical data at ASH 2025 and expanded collaborations with Incyte and AbCellera. Research and development expenses decreased to $21.7M, and net loss was $19.7M. An investor conference call is scheduled ...
11-12 12:01
AbCellera Biologics’ Earnings Call: Key Insights
Abcellera Biologics, Inc. (($ABCL)) has held its Q3 earnings call. Read on for ...
11-11 08:13
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Leerink Partners Downgrades AbCellera Biologics to Market Perform, Announces $4 Price Target
Leerink Partners analyst Faisal Khurshid downgrades AbCellera Biologics (NASDAQ:ABCL) from Outperform to Market Perform and announces $4 price target.
11-07 20:22
AbCellera Biologics Q3 EPS $(0.19) Misses $(0.17) Estimate, Sales $8.955M Beat $5.909M Estimate
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 12.43 percent. This is a 11.76 percent decrease over losses of $(0.17) per share
11-07 05:09
AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday?
After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto markets.
11-07 01:45
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
